Novartis has received marketing approval from the U.S. Food and Drug Administration for Zometa (zoledronic acid for injection) for the treatment of hypercalcemia of malignancy (HCM), the most common life-threatening metabolic complication associated with cancer.
Two clinical trials involving 275 patients showed significant differences between treatment with Zometa and the current standard treatment with respect to the percentage of complete responders, according to a company release.
No comments:
Post a Comment